CZO Ceapro Inc

Ceapro Inc. (TSX VENTURE:CZO) is pleased to announce that Dr. Bernhard Seifried
from Ceapro presented today the latest results obtained from one of Ceapro's
research programs using a supercritical drying technology. The presentation
entitled "Supercritical Fluid Drying of High Molecular Weight Biopolymers for
Particle Formulation and Delivery of Bioactives" was held under the
Pharmaceutical Applications stream of the International Symposium on
supercritical fluids currently ongoing in San Francisco at the Hyatt Regency
hotel. 


The goal from using this technology is to produce dry powder formulations of
certain Ceapro products currently sold as liquid formulations. From a
technological perspective, the process conditions facilitate the production of
preservative free, sterile products, powders, fibres, and agglomerates. The wide
range of very fine structures this technology produces facilitates easy
solubilisation which is essential for many drying technologies to be successful.


"While we have initially presented this technology as a powdered beta glucan
project, we realize that this technology might offer much more by becoming a
platform suitable for many water-soluble products.", stated Gilles Gagnon, CEO
of Ceapro. "With its potential usage for impregnation, coating and encapsulation
of Ceapro's bio-actives, it is expected that this technology would enable Ceapro
to offer product formulations which would be suitable for the transition to the
functional food, nutraceutical and potentially pharmaceutical areas", added Mr.
Gagnon.


Thus far the technology has been scaled up to pilot scale at the BioFoodTech
Centre in Charlottetown Prince Edward Island. Each scale up process requires
lead time to custom manufacture equipment that has been designed by Ceapro
scientists. "Each step of our scale up has gone exceptionally well and this
project has been a technical success to this point", said Dr. Bernhard Seifried,
research scientist at Ceapro. To date the beta glucan purity has exceeded 90%
and by adjusting the process conditions we have produced dried beta glucan in
the form of microfibrils, sponge type material, and free flowing powder, which
all show excellent solubilisation properties", added Dr Seifried. The next scale
up runs are scheduled for the next quarter when Ceapro intends to produce
multiple kilogram quantities of dried powder for evaluation by a food company.
Product samples have also been sent to a specialty pharmaceutical company for
testing.


"We congratulate Dr Seifried on his success to date on this totally novel
technology. The beta glucan products produced thus far are beyond our
expectations. Furthermore, applications of this technology might extend beyond
Ceapro's current products making this technology potentially attractive as an
out-license candidate to third parties requiring challenging drying solutions.
We look forward to continuing an aggressive path toward commercialization",
added Mr. Gagnon. 


About Ceapro Inc.

Ceapro Inc. is a Canadian growth-stage biotechnology company. Primary business
activities relate to the development and commercialization of active ingredients
for personal care and cosmetic industries using proprietary technology and
natural, renewable resources. The commercial line of natural active ingredients
include beta glucan, avenanthamides (colloidal oat extract), oat powder, oat
oil, oat peptides, and lupin peptides.


To learn more about Ceapro, visit www.ceapro.com

Ceapro (TSXV:CZO)
Gráfica de Acción Histórica
De May 2024 a Jun 2024

Ceapro (TSXV:CZO)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024